Lilly Ventures, the corporate venturing arm of pharmaceutical firm Eli Lilly, led a $25m extension yesterday to a series A round for US-based biotechnology company Symic that now stands at $40m.
Symic raised an initial $15m in a January 2015 first tranche that was also led by Lilly Ventures.
All of the first tranche’s participants returned for the expansion, including Mitsui Global Investment, a corporate venturing unit of diversified conglomerate Mitsui, and Danish state-backed Den Danske Forskningsfond.
The other…
